← All diseases Rare and hereditary disorders

Hereditary ATTR amyloidosis

Automatically tracked from PubMed and ClinicalTrials.gov, newest on top. Nothing ever disappears here: what you keep in your favorites remains findable. · RSS feed of this disease · only the strongest evidence

Search Period All yearsLast 12 monthsLast 5 years Topic All topicsGeneralNutrition and dietAlternative treatment methods Type of research Any type of researchHighest quality evidence only (79)Meta-analysis (11)Treatment guideline (1)Phase 3 study (29)Randomized trial (23)Systematic review (15)Clinical trial (345)Review article (146)Early study (phase 1 or 2) (7)Case report (135)Laboratory or animal study (8)Commentary or editorial (72) Studies currently recruiting participants only (34)

Filter

Publications and studies (1285)

• Performance of Clinical Scoring Systems in the Diagnosis of Transthyretin Amyloid Cardiomyopathy in a Diverse Patient Cohort. (2025/08/01) ♡
• Comparison of two genetic strategies for diagnostic work-up of hypertrophic cardiomyopathy: impact on the diagnosis of Fabry disease or transthyretin amyloidosis. (2025/06/10) ♡
• [(18)F]florbetapir PET for early detection of amyloidosis in patients with hereditary transthyretin amyloidosis polyneuropathy. (2025/06/07) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Effect of tafamidis therapy on physical function in patients with wild-type transthyretin cardiac amyloidosis. (2025/06/01) ♡
• Randomized researchiParticipants were divided into groups by lottery and compared with each other. This reduces the chance that a difference is due to something other than the treatment. The effect of trimetazidine on cardiac haemodynamics and mitochondrial function in wild-type transthyretin amyloidosis. (2025/06/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Pathogenesis, manifestations, diagnosis, and management of CNS complications in hereditary ATTR amyloidosis. (2025/06/01) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Small intestinal bacterial overgrowth in variant transthyretin amyloidosis (A-ATTRv). (2025/05/02) ♡
• Use of technetium-99m-pyrophosphate single-photon emission computed tomography/computed tomography in monitoring therapeutic changes of RNA interference therapeutics in patients with hereditary transthyretin amyloid cardiomyopathy. (2025/04/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. A phenomap of TTR amyloidosis to aid diagnostic screening. (2025/04/01) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Real-world characteristics and treatment of cardiac transthyretin amyloidosis: A multicentre, observational study. (2025/04/01) ♡
• Prevalence of transthyretin cardiac amyloidosis in undifferentiated heart failure with preserved ejection fraction. (2025/04/01) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Pre-symptomatic scintigraphic and genetic cascade screening in cardiac transthyretin amyloidosis. (2025/04/01) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Progression and prognostic significance of electrocardiographic findings in patients with cardiac amyloidosis. (2025/04/01) ♡
• Phase 3 studyiResearch in a large group of patients, the final step before a treatment can be approved. What comes out here carries significant weight. Long-Term Efficacy and Safety of Acoramidis in ATTR-CM: Initial Report From the Open-Label Extension of the ATTRibute-CM Trial. (2025/03/04) ♡
• Early-stage study (phase 1 or 2)iEarly research in a small group, primarily aimed at safety and dosage. Whether it actually works still needs to be determined afterward. PRX004 in variant amyloid transthyretin (ATTRv) amyloidosis: results of a phase 1, open-label, dose-escalation study. (2025/03/01) ♡
• Exploring cognitive functions and brain structure in Hereditary Transthyretin amyloidosis using brain MRI and neuropsychological assessment. (2025/03/01) ♡
• High frequency of occult transthyretin and apolipoprotein AI-type amyloid in aortic valves removed by valve replacement for aortic stenosis. (2025/03/01) ♡
• Involvement of bile acid in diarrhoea and therapeutic effect of colestimide in hereditary ATTR amyloidosis. (2025/03/01) ♡
• Oxidative conversion of transthyretin in formalin-fixed clinical amyloid samples results in the formation of the His90Asp and His90Asn variants. (2025/03/01) ♡
• Evolving knowledge of red flag clinical features associated with TTR p.(Val142Ile) in a diverse electronic health-record-linked biobank. (2025/03/01) ♡
• Right ventricular coupling predicts cardiopulmonary fitness in cardiac transthyretin amyloidosis. (2025/03/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Echocardiographic findings of patients with transthyretin amyloid cardiomyopathy. (2025/03/01) ♡
• Randomized researchiParticipants were divided into groups by lottery and compared with each other. This reduces the chance that a difference is due to something other than the treatment. Effects of eplontersen on symptoms of autonomic neuropathy in hereditary transthyretin-mediated amyloidosis: secondary analysis from the NEURO-TTRansform trial. (2025/03/01) ♡
• Randomized researchiParticipants were divided into groups by lottery and compared with each other. This reduces the chance that a difference is due to something other than the treatment. Five-Year Results With Patisiran for Hereditary Transthyretin Amyloidosis With Polyneuropathy: A Randomized Clinical Trial With Open-Label Extension. (2025/03/01) ♡
• Randomized researchiParticipants were divided into groups by lottery and compared with each other. This reduces the chance that a difference is due to something other than the treatment. Outpatient Worsening Heart Failure in Patients With Transthyretin Amyloidosis With Cardiomyopathy in the HELIOS-B Trial. (2025/02/25) ♡
• The Impact of Active Ascertainment on Sex-Specific Differences in the Prevalence and Phenotype of Transthyretin Cardiac Amyloidosis: The Screening for Cardiac Amyloidosis With Nuclear Imaging in Minority Populations Study. (2025/02/15) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Atrial fibrillation in transthyretin amyloidotic cardiomyopathy: prevalence and echocardiographic predictors. (2025/02/01) ♡
• Diagnostic delay in patients with sporadic hereditary transthyretin-mediated amyloidosis. (2025/02/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Hereditary Transthyretin Amyloidosis Polyneuropathy. (2025/02/01) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Prevalence of Cardiac Amyloidosis Among Elderly Patients With Recent-Onset Atrial Fibrillation: The PREVAL-ATTR Study. (2025/02/01) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Clinical outcomes for 2788 patients with transthyretin amyloidosis: Tafamidis meglumine early access program in France. (2025/02/01) ♡
• Hereditary vitreoretinal amyloidosis with transthyretin Gly83Arg variant, a long-term study. (2025/02/01) ♡
• Clinical significance of quantitative assessment of right ventricular amyloid burden with [(99m)Tc]Tc-DPD SPECT/CT in transthyretin cardiac amyloidosis. (2025/02/01) ♡
• Wild-type transthyretin cardiac amyloidosis and aortic stenosis: Can carpal tunnel syndrome help distinguish the chicken from the egg? (2025/02/01) ♡
• Prevalence of Pathogenic Transthyretin Gene Variants in the Rocky Mountain Region. (2025/02/01) ♡
• Electrophysiological Monitoring of Asymptomatic Transthyretin Mutation Carriers. (2025/02/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Disease-modifying therapies for amyloid transthyretin cardiomyopathy: Current and emerging medications. (2025/02/01) ♡
• Echocardiographic index of left ventricular performance for prognostication in transthyretin cardiac amyloidosis: the central role of stroke volume index. (2025/02/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Cardiac amyloidosis: when to suspect and how to confirm. (2025/02/01) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. A phenotypic comparison of the Romanian and French ATTRv cohorts: Glu54Gln founder pathogenic variant vs the most common variants in Western Europe. (2025/01/15) ♡
• Predictors of Early Death in Patients With Wild-Type Transthyretin Cardiac Amyloidosis. (2025/01/07) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Contextualizing the results of HELIOS-B in the broader landscape of clinical trials for the treatment of transthyretin cardiac amyloidosis. (2025/01/01) ♡
• Assessment of right ventricular myocardial stiffness by cardiac elastography in patients with transthyretin amyloidosis. (2025/01/01) ♡
• Prediction of Cardiac ATTR Depletion by NI006 (ALXN2220) Using Mechanistic PK/PD Modeling. (2025/01/01) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. A multicenter study of clinical predictors of positive pyrophosphate scintigraphy findings in the diagnosis of transthyretin amyloidosis. (2025/01/01) ♡
• Single-center analysis of cardiac amyloidosis using 99m Tc-HMDP imaging for diagnosis and evaluation after tafamidis treatment. (2025/01/01) ♡
• Prognosis of patients with wild-type transthyretin cardiac amyloidosis and non-sustained ventricular tachycardia. (2025/01/01) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Comprehensive Proteomics Profiling Identifies Circulating Biomarkers to Distinguish Hypertrophic Cardiomyopathy From Other Cardiomyopathies With Left Ventricular Hypertrophy. (2025/01/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Optimizing drug therapies in cardiac amyloidosis. (2025/01/01) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Transthyretin Cardiac Amyloidosis in Australia and New Zealand-A Multi-Site Snapshot for 2022. (2025/01/01) ♡

↑ Back to top

codex.care does not provide medical advice. Always discuss symptoms, medication, and treatment choices with your own healthcare provider.